SIBN
Bearish signalScored 2026-10-07 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
SI-BONE, Inc.
- Nom
- SI-BONE, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $962.7M
- Employés
- 376
- PDG
- Laura A. Francis
- Site web
- https://si-bone.com
- Marché
- ATECCNMDGMEDSNNSYKTNON
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 40 000 titres (~747 560,00 $ US)
- Insiders
- DUNN JEFFREY W
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$3,125,140
Avg sell (VWAP, 90d window) $19.37 vs last close $18.86 (-2.6%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$2,273,492 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-01
- Liquidity
- Thin $11,164,129/day · 20d vol
- Last synced
-
2026-10-08 21:10:55
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-05 | Maheshwari Anshul | Sell · S · 10b5-1 | 1,731 | $19.50 | $33,754 | Form 4 |
| 2026-10-02 | Maheshwari Anshul | Sell · S · 10b5-1 | 1,758 | $18.19 | $31,984 | Form 4 |
| 2026-10-02 | PISETSKY MICHAEL A. | Sell · S | 34 | $18.14 | $617 | Form 4 |
| 2026-10-01 | DUNN JEFFREY W | Sell · S | 20,000 | $18.47 | $369,400 | Form 4 |
| 2026-09-01 | DUNN JEFFREY W | Sell · S · 10b5-1 | 1,367 | $18.91 | $25,847 | Form 4 |
| 2026-08-24 | FRANCIS LAURA | Sell · S · 10b5-1 | 25,972 | $20.12 | $522,596 | Form 4 |
| 2026-08-24 | Maheshwari Anshul | Sell · S · 10b5-1 | 11,636 | $20.11 | $233,971 | Form 4 |
| 2026-08-21 | FRANCIS LAURA | Sell · S · 10b5-1 | 3,923 | $20.02 | $78,538 | Form 4 |
| 2026-08-21 | Maheshwari Anshul | Sell · S · 10b5-1 | 11,228 | $20.02 | $224,785 | Form 4 |
| 2026-08-20 | FRANCIS LAURA | Sell · S · 10b5-1 | 51,884 | $19.46 | $1,009,663 | Form 4 |
| 2026-08-19 | Maheshwari Anshul | Sell · S · 10b5-1 | 5,747 | $19.55 | $112,354 | Form 4 |
| 2026-08-17 | FRANCIS LAURA | Sell · S | 1,973 | $18.63 | $36,755 | Form 4 |
| 2026-08-17 | Maheshwari Anshul | Sell · S | 2,189 | $18.62 | $40,764 | Form 4 |
| 2026-08-17 | PISETSKY MICHAEL A. | Sell · S | 1,871 | $18.65 | $34,898 | Form 4 |
| 2026-08-03 | DUNN JEFFREY W | Sell · S | 20,000 | $18.46 | $369,214 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-07 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Despite strong liquidity (85), SIBN's weak catalyst score (25) with no actionable event-driven signal and a poor fundamental trend score (35) reflecting persistent operating losses make this an unattractive setup.
The first sentence of the analysis written for SIBN on 2026-10-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 8.55 · operating margin -11% — readings disagree
Suggested stop 18.43, nearest stored support minus 0.5 ATR(2.3% under the last close). Reward/risk to the next stored resistance is 1.42. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 79.6% | 79.0% | 78.8% | 85.2% | 88.4% | |
| Ebit Margin | -6.8% | -16.4% | -28.7% | -54.9% | -58.9% | |
| Ebitda Margin | -5.4% | -13.8% | -24.8% | -51.7% | -56.5% | |
| Operating Profit Margin | -11.1% | -21.1% | -33.8% | -56.0% | -57.3% | |
| Pretax Profit Margin | -9.4% | -18.5% | -31.2% | -57.6% | -62.8% | |
| Continuous Operations Profit Margin | -9.4% | -18.5% | -31.2% | -57.6% | -62.8% | |
| Net Profit Margin | -9.4% | -18.5% | -31.2% | -57.6% | -62.8% | |
| Bottom Line Profit Margin | -9.4% | -18.5% | -31.2% | -57.6% | -62.8% | |
| Current Ratio | 8.549 | 7.658 | 9.012 | 6.498 | 10.412 | |
| Quick Ratio | 7.208 | 6.660 | 8.149 | 5.682 | 9.732 | |
| Solvency Ratio | -0.265 | -0.418 | -0.621 | -0.976 | -0.971 | |
| Cash Ratio | 1.671 | 1.288 | 1.418 | 0.978 | 3.755 | |
| Price To Earnings Ratio | -44.818 | -18.693 | -18.575 | -7.598 | -12.988 | |
| Price To Earnings Growth Ratio | 1.084 | 0.556 | 0.504 | -1.624 | -0.928 | |
| Forward Price To Earnings Growth Ratio | 1.084 | 0.556 | 0.504 | -1.624 | -0.928 | |
| Price To Earnings Diluted Ratio | -44.818 | -18.693 | -18.575 | -7.598 | -12.988 | |
| Price To Earnings Diluted Growth Ratio | 1.084 | 0.556 | 0.504 | -1.624 | -0.928 | |
| Price To Book Ratio | 4.833 | 3.482 | 4.762 | 4.732 | 5.477 | |
| Price To Sales Ratio | 4.270 | 3.478 | 5.808 | 4.371 | 8.166 | |
| Price To Free Cash Flow Ratio | -94.397 | -25.363 | -30.424 | -9.092 | -16.031 | |
| Price To Operating Cash Flow Ratio | -1,271.072 | -46.790 | -43.103 | -11.167 | -18.622 | |
| Debt To Assets Ratio | 0.005 | 0.163 | 0.169 | 0.250 | 0.212 | |
| Debt To Equity Ratio | 0.006 | 0.224 | 0.230 | 0.401 | 0.301 | |
| Debt To Capital Ratio | 0.006 | 0.183 | 0.187 | 0.286 | 0.231 | |
| Long Term Debt To Capital Ratio | 0.001 | 0.175 | 0.176 | 0.264 | 0.206 | |
| Financial Leverage Ratio | 1.344 | 1.380 | 1.360 | 1.603 | 1.417 | |
| Working Capital Turnover Ratio | 1.082 | 0.907 | 0.913 | 0.773 | 0.496 | |
| Operating Cash Flow Ratio | -0.027 | -0.458 | -0.798 | -1.967 | -2.341 | |
| Operating Cash Flow Sales Ratio | -0.003 | -0.074 | -0.135 | -0.391 | -0.439 | |
| Free Cash Flow Operating Cash Flow Ratio | 13.465 | 1.845 | 1.417 | 1.228 | 1.162 | |
| Debt Service Coverage Ratio | -1.751 | -6.713 | -9.950 | -19.505 | -9.500 | |
| Interest Coverage Ratio | -4.227 | -10.247 | -13.556 | -21.145 | -9.631 | |
| Short Term Operating Cash Flow Coverage Ratio | -0.715 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.603 | -0.331 | -0.480 | -1.056 | -0.977 | |
| Capital Expenditure Coverage Ratio | -0.080 | -1.184 | -2.399 | -4.382 | -6.188 | |
| Dividend Paid And Capex Coverage Ratio | -0.080 | -1.184 | -2.399 | -4.382 | -6.188 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -74.899 | -25.284 | -23.582 | -8.800 | -13.993 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 79.6% | ▲0.5% | ▼-2.6% |
| Ebit Margin | -6.8% | ▲9.7% | ▲26.4% |
| Ebitda Margin | -5.4% | ▲8.4% | ▲25.0% |
| Operating Profit Margin | -11.1% | ▲10.0% | ▲24.8% |
| Pretax Profit Margin | -9.4% | ▲9.1% | ▲26.5% |
| Continuous Operations Profit Margin | -9.4% | ▲9.1% | ▲26.5% |
| Net Profit Margin | -9.4% | ▲9.1% | ▲26.5% |
| Bottom Line Profit Margin | -9.4% | ▲9.1% | ▲26.5% |
| Current Ratio | 8.549 | ▲0.891 | ▲0.123 |
| Quick Ratio | 7.208 | ▲0.548 | ▼-0.278 |
| Solvency Ratio | -0.265 | ▲0.153 | ▲0.385 |
| Cash Ratio | 1.671 | ▲0.383 | ▼-0.151 |
| Price To Earnings Ratio | -44.818 | ▼-26.125 | ▼-24.284 |
| Price To Earnings Growth Ratio | 1.084 | ▲0.528 | ▲1.166 |
| Forward Price To Earnings Growth Ratio | 1.084 | ▲0.528 | ▲1.166 |
| Price To Earnings Diluted Ratio | -44.818 | ▼-26.125 | ▼-24.284 |
| Price To Earnings Diluted Growth Ratio | 1.084 | ▲0.528 | ▲1.166 |
| Price To Book Ratio | 4.833 | ▲1.351 | ▲0.176 |
| Price To Sales Ratio | 4.270 | ▲0.793 | ▼-0.948 |
| Price To Free Cash Flow Ratio | -94.397 | ▼-69.034 | ▼-59.336 |
| Price To Operating Cash Flow Ratio | -1271.072 | ▼-1224.282 | ▼-992.921 |
| Debt To Assets Ratio | 0.005 | ▼-0.158 | ▼-0.155 |
| Debt To Equity Ratio | 0.006 | ▼-0.218 | ▼-0.226 |
| Debt To Capital Ratio | 0.006 | ▼-0.177 | ▼-0.173 |
| Long Term Debt To Capital Ratio | 0.001 | ▼-0.174 | ▼-0.163 |
| Financial Leverage Ratio | 1.344 | ▼-0.036 | ▼-0.077 |
| Working Capital Turnover Ratio | 1.082 | ▲0.175 | ▲0.248 |
| Operating Cash Flow Ratio | -0.027 | ▲0.431 | ▲1.091 |
| Operating Cash Flow Sales Ratio | -0.003 | ▲0.071 | ▲0.205 |
| Free Cash Flow Operating Cash Flow Ratio | 13.465 | ▲11.620 | ▲9.642 |
| Debt Service Coverage Ratio | -1.751 | ▲4.962 | ▲7.733 |
| Interest Coverage Ratio | -4.227 | ▲6.020 | ▲7.534 |
| Short Term Operating Cash Flow Coverage Ratio | -0.715 | ▼-0.715 | ▼-0.572 |
| Operating Cash Flow Coverage Ratio | -0.603 | ▼-0.272 | ▲0.086 |
| Capital Expenditure Coverage Ratio | -0.080 | ▲1.103 | ▲2.766 |
| Dividend Paid And Capex Coverage Ratio | -0.080 | ▲1.103 | ▲2.766 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -74.899 | ▼-49.616 | ▼-45.588 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $858.0M | $581.4M | $806.6M | $465.1M | $736.2M | |
| Enterprise value | $816.9M | $583.9M | $812.3M | $483.9M | $713.2M | |
| EV / Sales | 4.07x | 3.49x | 5.85x | 4.55x | 7.91x | |
| EV / Op. cash flow | -1210.15x | -46.99x | -43.41x | -11.62x | -18.04x | |
| EV / Free cash flow | -89.87x | -25.47x | -30.64x | -9.46x | -15.53x | |
| EV / EBITDA | -74.90x | -25.28x | -23.58x | -8.80x | -13.99x | |
| Net debt / EBITDA | 3.77x | -0.11x | -0.17x | -0.34x | 0.45x | |
| Current ratio | 8.55x | 7.66x | 9.01x | 6.50x | 10.41x | |
| Income quality | 0.04x | 0.40x | 0.43x | 0.68x | 0.70x | |
| Graham net-net | $3 | $3 | $3 | $2 | $3 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 138.8% | 112.5% | 108.7% | 104.8% | 106.6% | |
| Working capital | $190.8M | $180.6M | $187.9M | $116.4M | $159.0M | |
| Invested capital | $213.2M | $203.0M | $206.6M | $136.0M | $173.2M | |
| Return on assets | -7.9% | -13.4% | -18.8% | -38.9% | -29.7% | |
| Operating ROA | -9.5% | -15.3% | -24.2% | -34.3% | -25.0% | |
| Return on tangible assets | -7.9% | -13.4% | -18.8% | -38.9% | -29.7% | |
| Return on equity | -10.7% | -18.5% | -25.6% | -62.3% | -42.1% | |
| Return on invested capital | -10.4% | -17.2% | -22.5% | -43.3% | -29.5% | |
| Return on capital employed | -10.5% | -17.3% | -22.7% | -43.7% | -29.8% | |
| Earnings yield | -2.2% | -5.3% | -5.4% | -13.2% | -7.7% | |
| Free cash flow yield | -1.1% | -3.9% | -3.3% | -11.0% | -6.2% | |
| Capex / Op. cash flow | -1246.5% | -84.5% | -41.7% | -22.8% | -16.2% | |
| Capex / Depreciation | 309.5% | 239.7% | 143.7% | 275.4% | 306.3% | |
| Capex / Sales | 4.2% | 6.3% | 5.6% | 8.9% | 7.1% | |
| SG&A / Sales | 82.0% | 90.2% | 101.8% | 128.5% | 131.9% | |
| R&D / Sales | 8.7% | 9.9% | 10.8% | 12.8% | 13.8% | |
| Stock comp / Sales | 12.7% | 15.5% | 17.3% | 21.7% | 18.7% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 54d | 60d | 58d | 71d | 58d | |
| Days payables outstanding | 41d | 68d | 57d | 146d | 112d | |
| Operating cycle | 356d | 342d | 309d | 473d | 460d | |
| Cash conversion cycle | 315d | 274d | 252d | 327d | 348d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-06 Analyzing SiBone (NASDAQ:SIBN) & Integer (NYSE:ITGR) Integer (NYSE: ITGR - Get Free Report) and SiBone (NASDAQ: SIBN - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership. Profitability This table compares Integer and SiBone''s net margins, return
- 2026-09-28 SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone
- 2026-09-14 SI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript SI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-08-31 SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026 SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Monday, September 14, 2026, at 8:30 a.m. Pacific Time/ 11:30 a.m. Eastern Time.
- 2026-08-25 Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy? Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-08-24 Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here''s is How to Trade The mean of analysts'' price targets for Si-Bone (SIBN) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 2026-08-06 Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect? The consensus price target hints at a 38.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 2026-08-05 SiBone Q2 Earnings Call Highlights SiBone (NASDAQ: SIBN) reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss as procedure volumes increased across its U.S. business and international demand rose for its expanded product portfolio. Worldwide revenue reached $56 million for the quarter ended June 30, while U.S. revenue increased 14.7% to $53.2 million. International revenue grew 25.9% to
- 2026-08-04 SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript
- 2026-08-03 Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates Si-Bone (SIBN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.14 per share a year ago.